Deng Yan, Li Ai-Min, Zhao Xin-Mei, Song Zhang-Juan, Liu Si-De
Department of Gastroenterology, Southern Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China.
Department of Gastroenterology, Haicang Hospital, Xiamen, Fujian 361000, P.R. China.
Oncol Lett. 2017 Mar;13(3):1228-1234. doi: 10.3892/ol.2016.5537. Epub 2016 Dec 27.
The expression of tumor protein 53-inducible nuclear protein 1 (TP53INP1) is upregulated in certain cancers and downregulated in others. However, its expression in hepatocellular carcinoma (HCC) is not clear. The present study aimed to investigate the expression and prognostic value of TP53INP1 and its association with clinicopathological parameters in HCC. TP53INP1 expression in HCC tissue samples was examined via immunohistochemistry, western blotting and reverse transcription-quantitative polymerase chain reaction. Expression was categorized as high or low. The correlations of TP53INP1 expression with clinical characteristics and patients' prognoses were determined. TP53INP1 was frequently decreased in HCC tissues compared with adjacent non-tumorous liver tissues. This decreased expression was significantly associated with American Joint Committee on Cancer stage (P=0.014) and vascular invasion (P=0.024). Kaplan-Meier analysis further revealed that recurrence-free survival (RFS) (P=0.001) and overall survival (OS) (P=0.002) were significantly worse among patients with low TP53INP1 expression than among those with high TP53INP1 expression. In addition, multivariate analyses revealed that TP53INP1 was an independent predictor of OS [hazard ratio (HR)=2.680, 95% confidence interval (CI)=1.087-6.608, P=0.032) and RFS (HR=2.284, 95% CI=1.157-4.511, P=0.017). In conclusion, the expression of TP53INP1 was decreased in HCC, and TP53INP1 downregulation was an independent predictor of poor prognosis in patients with HCC.
肿瘤蛋白53诱导核蛋白1（TP53INP1）的表达在某些癌症中上调，而在其他癌症中下调。然而，其在肝细胞癌（HCC）中的表达尚不清楚。本研究旨在探讨TP53INP1在HCC中的表达及预后价值，以及其与临床病理参数的关系。通过免疫组织化学、蛋白质印迹法和逆转录-定量聚合酶链反应检测HCC组织样本中TP53INP1的表达。将表达分为高表达或低表达。确定TP53INP1表达与临床特征和患者预后的相关性。与相邻的非肿瘤肝组织相比，HCC组织中TP53INP1经常降低。这种降低的表达与美国癌症联合委员会分期（P=0.014）和血管侵犯（P=0.024）显著相关。Kaplan-Meier分析进一步显示，TP53INP1低表达患者的无复发生存期（RFS）（P=0.001）和总生存期（OS）（P=0.002）明显比TP53INP1高表达患者差。此外，多因素分析显示，TP53INP1是OS[风险比（HR）=2.680，95%置信区间（CI）=1.087-6.608，P=0.032]和RFS（HR=2.284，95%CI=1.157-4.511，P=0.017）的独立预测因子。总之，HCC中TP53INP1的表达降低，TP53INP1下调是HCC患者预后不良的独立预测因子。
